Angiodysplasia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Nikita Singh (talk | contribs) No edit summary |
Nikita Singh (talk | contribs) No edit summary |
||
Line 5: | Line 5: | ||
{{PleaseHelp}} | {{PleaseHelp}} | ||
==Agiodysplasia cost-effectiveness of therapy== | |||
Currently, endoscopy is the diagnostic modality of choice, and argon plasma coagulation is the most cost-effective endoscopic therapy for the bleeding lesions. | Currently, endoscopy is the diagnostic modality of choice, and argon plasma coagulation is the most cost-effective endoscopic therapy for the bleeding lesions. | ||
Revision as of 23:04, 3 September 2021
Angiodysplasia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Angiodysplasia cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Angiodysplasia cost-effectiveness of therapy |
Risk calculators and risk factors for Angiodysplasia cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Nikita Singh, M.D.[2]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Agiodysplasia cost-effectiveness of therapy
Currently, endoscopy is the diagnostic modality of choice, and argon plasma coagulation is the most cost-effective endoscopic therapy for the bleeding lesions.